Small Molecule Modulators of Polyglutamine Protein Interactions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders caused by protein misfolding and aggregation, such as Huntington's disease, lack effective methods to inhibit or modulate the aberrant association of proteins, leading to neuronal pathogenesis and cellular dysfunction.
Innovation Solution
Development of specific compounds represented by Formulas I-IV and V(a)-V(u) that can inhibit or facilitate protein-protein interactions, potentially preventing or treating diseases by modulating protein aggregation, formulated into pharmaceutical compositions for administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for neurodegenerative disorders, then current therapeutic approaches are maintained, but effective inhibition of protein aggregation is not achieved
Solution Approach 1:
The patent introduces small molecule compounds as intermediary substances that bind to polyglutamine-containing polypeptides and modulate their interaction with other proteins. These compounds act as mediators between the pathological polypeptides and the cellular environment, preventing harmful protein-protein interactions that lead to aggregation and neuronal damage.
Solution Approach 2:
The invention changes the biochemical parameters of polyglutamine-containing polypeptides by introducing compounds that alter their interaction properties. The compounds modify the physical-chemical characteristics of the polypeptide-protein interactions, thereby preventing aggregation without changing the underlying genetic mutation.
2Reliability
If protein-protein interactions are modulated to prevent aggregation, then therapeutic benefit is achieved, but specificity of compound action must be maintained
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (such as aromatic rings, hydrogen bonding capabilities, and hydrophobic regions) that enable selective interaction with polyglutamine-containing polypeptides. This localized molecular design ensures that the compounds act specifically on target polypeptides without broadly affecting all protein interactions in the cell.
Data Source
AI summary
The present invention is based, in part, on assays we conducted that revealed compounds that may be used to treat or prevent diseases characterized by an abnormal or undesirable association of one protein with another.